TA50 Stock Chart & Stats
€0.52
€0.05(44.64%)
At close: 4:00 PM EST
€0.52
€0.05(44.64%)
Day’s Range― - ―
52-Week Range€0.04 - €1.33
Previous CloseN/A
Volume100.00
Average Volume (3M)612.00
Market Cap
€233.16M
Enterprise Value€156.69
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-107.85
Next Earnings
Aug 31, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding274,627,900
10 Day Avg. Volume1,838
30 Day Avg. Volume612
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Targovax ASA News
TA50 FAQ
What was Targovax ASA’s price range in the past 12 months?
Targovax ASA lowest stock price was €0.04 and its highest was €1.33 in the past 12 months.
What is Targovax ASA’s market cap?
Targovax ASA’s market cap is €233.16M.
When is Targovax ASA’s upcoming earnings report date?
Targovax ASA’s upcoming earnings report date is Aug 31, 2026 which is in 32 days.
How were Targovax ASA’s earnings last quarter?
Targovax ASA released its earnings results on Apr 15, 2026. The company reported -€0.016 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Targovax ASA overvalued?
According to Wall Street analysts Targovax ASA’s price is currently Overvalued.
Does Targovax ASA pay dividends?
Targovax ASA does not currently pay dividends.
What is Targovax ASA’s EPS estimate?
Targovax ASA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Targovax ASA have?
Targovax ASA has 274,627,900 shares outstanding.
What happened to Targovax ASA’s price movement after its last earnings report?
Targovax ASA reported an EPS of -€0.016 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -9.371%.
Which hedge fund is a major shareholder of Targovax ASA?
Currently, no hedge funds are holding shares in DE:TA50
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Targovax ASA
Circio Holding ASA, a biotechnology firm based in Oslo, Norway, and founded in 2010, specializes in the development of advanced circular RNA and immunotherapy treatments. Among its key innovations is TG01, a cancer vaccine aimed at specific driver mutations, which is currently progressing through three clinical trials for indications including multiple myeloma, pancreatic cancer, and lung cancer. The company also pioneers the circVec circRNA vector platform, an adaptable genetic module designed to facilitate the creation of diverse functional circular RNAs within human cells. This circVec platform is further supported by a collaborative agreement with Certest Biotec, S.L., focusing on its formulation. Formerly known as Targovax ASA, the company officially rebranded to Circio Holding ASA in May 2023.